|
Miralles-Lopez JC, Andujar-Espinosa R, Bravo-Gutierrez FJ, Cabrejos-Perotti S, Ramirez-Hernandez M, Diaz-Chantar C, Pajaron Fernandez MJ, Valverde-Molina J, Perez-Fernandez V; RE-ASGRAMUR GROUP. Tezepelumab in Patients With Severe Asthma: Response at 3 Months. J Investig Allergol Clin Immunol. 2025 Apr 22;35(2):132-134. doi: 10.18176/jiaci.1041. Epub 2024 Nov 25. No abstract available. PubMed PMID: 39584417.
AÑO: 2025; IF: 4.8
|
|
Miralles-López J.C., Bravo-Gutierrez F.J., Andújar-Espinosa R., Castilla-Martínez M., Díaz-Chantar C., Ramírez-Hernández M., Cabrejos-Perotti S., Avilés-Inglés M.J., Ibarra-Calabuig I., Reyes-Cotes M.H., Pajarón-Fernández M.J., Bernabéu-Mora R., Alcalde-Rumayor C., Alemany-Francés M.L., Valverde-Molina J., Pérez-Fernández V. Real-life effectiveness of tezepelumab in severe asthma. Allergologia et immunopathologia. 2025. 53:163-173. 10.15586/aei.v53i2.1326
AÑO: 2025; IF: 2.1
|
|
Miralles-López J.C., Petryk Y.P., Cortés Collado J.J., Bravo-Gutierrez F.J., Andújar-Espinosa R., Castilla-Martínez M., Díaz-Chantar C., Cabrejos-Perotti S., Valverde-Molina J., Pérez-Fernández V. Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice. Allergologia Et Immunopathologia. 2025. 53:193-196. 10.15586/aei.v53i5.1448
AÑO: 2025; IF: 2.1
|